Podcasts about patients

Bill Roggio analyzes the ISIS allegiance of Australian shooters, distinguishing ISIS's immediate caliphate goals from Al-Qaeda's patient state-building. He warns that while Al-Qaeda focuses on consolidating control in places like Somalia(Al-Shabaab), they remain a potent global threat capable of launching external attacks when strategically advantageous. 1842 Afghanistan

In this episode of Pray the Word on Revelation 1:9, David Platt calls us to live the Christian life with patient endurance.Over 3 billion people have never heard the gospel.At Radical, we're fueling 140 gospel projects in 42 countries to change that—equipping local leaders and mobilizing believers where Jesus is least known.Through December 31, every gift is doubled up to $750,000.Would you pray about being part of this?Learn more at Radical.net/everywhereExplore more content from Radical.

Scott Capozza and I could have been cloned in a bad lab experiment. Both diagnosed with cancer in our early twenties. Both raised on dial-up and mixtapes. Both now boy-girl twin dads with speech-therapist wives and a lifelong grudge against insurance companies. Scott is the first and only full-time oncology physical therapist at Yale New Haven Health, which means if he catches a cold, cancer rehab in Connecticut flatlines. He's part of a small, stubborn tribe of providers who believe movement belongs in cancer care, not just after it. We talked about sperm banking in the nineties, marathon training during chemo, and what it means to be told you're “otherwise healthy” when your lungs, ears, and fertility disagree. Scott's proof that survivorship is not a finish line. It's an endurance event with no medals, just perspective.RELATED LINKSScott Capozza on LinkedIn: https://www.linkedin.com/in/scott-capozza-a68873257Yale New Haven Health: https://www.ynhh.orgExercising Through Cancer: https://www.exercisingthroughcancer.com/team/scott-capozza-pt-msptProfiles in Survivorship – Yale Medicine: https://medicine.yale.edu/news-article/profiles-in-survivorship-scott-capozzaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In the competitive world of medical aesthetics, many practices struggle because they view "sales" as a dirty word. But here's the truth: sales is simply an extension of patient care. Terri Ross, a top industry expert, argues that the most successful cash-based practices shift their focus from pushing procedures to consulting on solutions. Your Actionable Takeaway: Abandon the "icky" sales stigma. Embrace emotional selling by asking deep, open-ended questions to uncover the true motivations behind a patient's desire for treatment. Patients buy on feeling, not just facts. When you genuinely serve, you automatically sell.

We'll bring you the latest on the investigation into the deaths of Rob Reiner and his wife Michele. An LA nursing home is still open despite three citations for deaths of its residents. Plus changes are coming to parking rates in Santa Monica. Support The L.A. Report by donating at LAist.com/join and by visiting https://laist.com Visit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency!Support the show: https://laist.com

Retatrutide is years away from FDA approval and yet the fight over access, price, control of this medication is already well underway. That's what this podcast is going to be about today. There's well over a hundred thousand people by my estimates who are already on some form of this medication today. And that should tell you enough about how disruptive this molecule is and will be. It is a game changer among game changer. We've been talking about it for three years here at On The Pen, well before any of your favorite gym bros were talking about Retatrutide. We were talking about Reta, who tried Retatrutide here at On The Pen. And that's because we identified this triple agonist as a game changer among game changers. So This is going to be a very Retatrutide heavy episode, and so I hope you'll join us and stick with us if this is a topic you enjoy, because I think this is really going to effectively lay the groundwork for what accessibility to this medication will look like. So let's get into it. Welcome to the On The Pen Podcast with your host, Dave Knapp. Welcome to the On The Pen, the weekly dose podcast. This is our weekly roundup in incretin memetic news. And frankly, there's no news that is bigger than Reta-Trutide news. Just find me any news that is bigger than the data that we got on Reta-Trutide. Now, we already did a video about the Triumph Phase II clinical trials that we got in osteoarthritis of the knee. You can go back and check out that video if you'd like more data. So we're not gonna super... rehash the data. We'll go over at a high level what the data showed us. We're not going to go over how the medicine works, because by now we all know that it's the triple agonist, right? If terzapatide was a dual agonist, GLP-GIP, Retatrutide is the triple agonist that adds to it a glucagon component, which is absolutely just shredding, shredding liver fat. It is absolutely revving up people's metabolism and showing a tremendous amount of weight loss. So let's get into what the weight loss looked like in this first trial, because there are longer obesity trials where, where the primary outcome is the weight loss this was again a specific trial in measuring pain reduction in folks with osteoarthritis of the knee but check out these numbers these are placebo adjusted meaning it's taking the two percent out that people lost on placebo but looking at these numbers Folks on one milligram over forty eight weeks lost seventeen percent. They bumped up to four milligrams. Those folks lost twenty two percent. So right there at the lowest dose, you're already reaching the efficacy of today's drugs that are on the market, like triseptide and semaglutide in their various forms. If you bumped up to eight milligrams, you saw twenty four percent placebo adjusted weight loss and at twelve milligrams, twenty six point four percent weight loss. Adding back in that two percent of the placebo that those on placebo loss, that's twenty eight point four percent weight loss in these forty eight weeks at the highest dose. When you adjust for some of the more real world outcomes, you kind of ding the numbers a little bit based upon people who quit the drug, et cetera. Those numbers look more like a twenty percent weight loss and twenty three point seven percent weight loss at the highest dose. But even then, you're still seeing a drug that is better than the current drugs that are on the market. around forty eight percent of patients on Retatrutide lost greater than twenty five percent. And then if you were at that twelve twelve milligram dose, that highest dose patients lost fifty nine percent of patients lost more than twenty five percent of their body weight. There was a subset that lost thirty percent of their body weight and some even over thirty five percent of their body weight on Retatrutide. So the lower doses compete with today's best drugs and the upper doses are entering into bariatric surgery level weight loss. And that's putting the whole obesity system on notice and probably a lot of surgeons nervous because typical body weight loss was something like the street sleeve gastrectomy. For example, it's about eighteen to twenty five percent body weight. The Roux-en-Y gastric bypass twenty five to thirty five percent weight loss or the duodenal switch thirty to forty percent weight loss. So the upper doses of Ritutrutide overlap with sleeve and bypass outcomes without any surgery. It's incredible. It is a game changer among game changer. It is the new benchmark in obesity medicine. And there's actually more data, like I said, landing in later twenty twenty six. The longer duration will historically, if history is a marker, equal more weight loss than we even see here at this forty eight weeks. We have an interview that will be airing later this week on our channel and on our podcast with our friend Mimi from Australia who just wrapped up her clinical trial on Retatrutide. They ended it like ten weeks early on her, which was a huge bummer to her. So we're going to hear from her because she had to end abruptly. We're going to hear her story, an incredible story. She's one of those folks that got up that thirty five percent body weight loss in the time that she was on Retatrutide. So, this is just showing you that these drugs are not simply an alternative to bariatric surgery. We are approaching a point in time where these are on par with bariatric surgery, and as people are on this Reta-Trutide trial, you see that these numbers aren't plateauing either. So we will see stronger weight loss numbers the longer that these folks are on this trial. And I think you'll see some of those numbers in that population of folks on the higher doses eclipse maybe even some of what we see with some of these bariatric surgeries. the real story that i think is taking shape here is not in how powerful Retatrutide is because we've literally been expecting or anticipating this kind of data for more than three years at on the pin we've been talking about this and i think that's sort of reflected in the fact that you didn't see this massive spike in eli lilly stock wall street was expecting this as well Um, so it was on par, I think with expectations, but the expectations are astronomical compared to previous options that were available to patients and all the innovation in the world. All of these drugs, we talked at last week about WV, E double Oh seven, the James Bond of weight loss that targets fat, not only targets fat loss, but it also targets the promotion of building of, of lean muscle mass. We're talking about an insane future in obesity medicine. But none of it means anything if people can't access it. And that's really where we are today in terms of ensuring that there's going to be an option for everyone. And that's sort of what I want to get into today, because Lilly wants Retatrutide to be classified as a biologic, so not a traditional small molecule drug like you've seen every other incretin and nutrient-stimulated hormone-treating obesity on the market to date. They're trying to get this classified as a biologic. Now, we talked about this before on the podcast. That matters in three major ways. It affects the exclusivity length of time that a pharmaceutical company has on a drug. That goes from, I believe, five years of market exclusivity to twelve. It affects compounding rules because biologics cannot be compounded. And then that gives the pharmaceutical companies a tremendous amount of pricing power in the marketplace, because essentially there's no competition and there's no competition for a long time. But this whole argument about getting this classified as a biologic is not about safety. It's about protection and we're going to get into it. So let's explain this here. This is why Retatrutide really is not a biologic arguably. So biologics are large proteins. There are hundreds of or even thousands of amino acids grown in living cells that are sensitive to tiny manufacturing changes. Retatrutide is a short chain peptide. It's chemically synthesized and it is below the traditional biological size thresholds when it comes to how those things are defined. We'll just leave it at that. So even though it acts like a biologic in the body, it's made like a drug. It's made like a small molecule drug. And if it's treated as a drug, they get, like I said, five years of market exclusivity. Now, really a lot of confusion around what this means, but essentially the first five years of the life of a drug, the patent can be challenged for a number of reasons. We've seen patent challenges right now are going on in the courts for both semaglutide and terzepatide. But these companies are guaranteed that five years of market exclusivity, no matter how those patent lawsuits shake out. That five years jumps to twelve years with the biologic. So ultimately, there's no biosimilars that are allowed during that twelve year window. Again, with terzapatidin and semaglutide, it's five years. They could lose their market exclusivity within five years of the release of the patent. twelve years with a biologic. So if they lose their patent challenges on Trezabitide, they still have some time left with market exclusivity for the drug. They likely will not lose those, but that jumps to twelve years. And I think the most important thing to understand about the reclassification of Reta-Trutide to a biologic would mean that, 503A and 503B pharmacies are effectively locked out of compounding this medication, 503Bs would have some latitude arguably, but they would face extreme barriers. Routine compounding becomes legally and technically restricted because biological status doesn't slow compounding down. It actually shuts the door or almost completely shuts the door. Biologics not only would allow Lilly to have longer market exclusivity, no compounding, but it would allow them to command a higher price in the marketplace because A, they get this designation and there's an assumption when they bring this to market that they're harder to manufacture, that they're harder to copy, that there are fewer negotiating alternatives for payers. They can command a higher price with the insurance companies, and the price pressure stays muted for much longer because, again, you don't have those pressures of compounding. You don't have the pressures externally from lawsuits that could end your market exclusivity in that first five years of the drug's existence. So there's just a lot of price pressure upwards on a biologic compared to a normal small molecule drug. And when there's no credible alternative or backup option, which to Retatrutide, there wouldn't be, it'd be the first drug that has bariatric surgery level results. The prices won't come down. They'll command a massive price and the prices won't come down. So let's talk about where this currently stands because ultimately the Eli Lilly went to the FDA. We've been covering this for well over a year, maybe close to two years now, a year and a half at least. Lily went to the FDA, they said, we want this classified as a biologic, here are the reasons why. The FDA initially said, no, we're not gonna do that. So Lily challenged that decision in court. So the point that we're at today is the court told the FDA to reconsider and better explain itself So the first no given to the FDA to Lilly didn't stick. The courts looked at it and they said, you need a better, you need to reconsider your decision and you need to explain your decision better to Lilly. So ultimately we're sitting now at the point where the court has made its decision that the FDA has to go back and now we await basically what the FDA has to say on this. But if this thing is classified as a biologic, that would be a massive massive loss for patients. Now, again, we're, we're focusing on the accessibility of this drug into the future. And, and I think that this is an important conversation to have. One of the interesting points that I have to bring into the conversation is the fact that I got to sit in on a, on a closed session question and answer with the media. I didn't get to answer or, excuse me, excuse me, ask a question at this time, but shortly after the most favored nations announcement, with eli lilly and the trump administration in the oval office that day there was a press briefing that i was invited to dave ricks was asked by max bayer reporter of endpoints who we've interviewed here on this very podcast and he was asked was Retatrutide included in the most favored nations discussions meaning will we get a cash pay version of Retatrutide uh that is you know circumventing the pbms uh will we get these cheaper prices will will it be be two hundred fifty dollars also and there was a hard no there was a hard no like no that was not included that was not part of these discussions even though what we heard from the trump administration was that those these companies that were jumping on to the most favored nations agreement were also agreeing to offer future drugs at most favored nations pricing now was lily saying that no they're not going to offer it at the it wasn't part of the negotiations in terms of the price points that they had discussed for triseptide maybe or did it mean altogether there won't be a cash pay option of this medication i don't know um that we would love to get clarity on But I highly doubt we're going to get any more information than necessary at this point in time. So, Reta-Trutide is being positioned to be a drug that, and well so, should be offered at a premium. This is a drug that is far exceeding the current drugs that are on the market. I think that we're gonna see even the indications of Reta-Trutide far beyond simple obesity, but it is going to be their crown jewel for the next decade, more than likely. Reta-Trutide is going to be a massive drug, and so they're attempting to build a moat around it. And these are things that we need to be aware of as a community so that we can hold our positions and conversations about these and basically, you know, be able to articulate to people in positions of power like this is an important thing to us. This is an important thing in the advocacy of obesity and sort of the next frontier of the fight of accessibility, which marches on. each and every day because of course the current drugs, while as great as they are and as much as access is expanding, there are still people with sicker or rather more advanced versions of metabolic disease that are gonna need these newer treatments and price is going to be a huge factor. So let's talk about the gray market right now because I think it's also nearly impossible to talk about this topic without including a discussion about the gray market because there are, as I mentioned at the outset, hundreds of thousands of people on this medication already. So research grade Retatrutide exists. It's in the gray markets of the Internet. It's where people are going and they're buying, you know, basically versions of these these peptides that are made in factories overseas. They're being imported into the United States, oftentimes illicitly in shipments that are marked as something else. The FDA has tried to crack down. There's no doctor involved in this. It's a very, that's why it's called the gray market, right? So it's not a prescription medicine, but the demand for this is massive. And all you have to do is really scroll your TikTok for about fifteen minutes. You're going to come across a insane amount of content on the topic of Retatrutide. An insane amount of, and oftentimes, you know, what I find most disturbing is oftentimes it looks like very young people. very young people taking Retatrutide. Crazy, it's crazy. But the demand is massive and there's a whole gray market for it proliferating over on TikTok and in the far reaches of the internet. And I would estimate that tens, if not hundreds of thousands of people are already or have already used it. And I think it's a testament to a to to the effectiveness of this drug. It's also a testament to the fact that there needs to be more guardrails, I think, around this stuff than there currently is, because gray markets appear and they thrive when legal access lags the reality of the demand for the medication. And you saw this earlier this week as we launched a petition to fight back against the Safe Drug Act of twenty twenty five, a drug, a drug act that is in theory designed to put guardrails around compounding. But in practice, I think is creating a new battlefield for Eli Lilly and Novo Nordisk to shut down compounding on the current classes of medications, which is why We as a community need to be loud about our opposition to it. If they were really concerned about the safety of compounds, they would do two very simple things. They would require reporting around the active pharmaceutical ingredient of a compound. Patients ought to be able to know where the actual source of their medication is coming from. And they should know that those places are FDA approved and inspected. And the second thing is they should require adverse event reporting. Those are required of 503Bs. They should be required of 503As as well. 503As are making a tremendous amount of money. They're making thousands and thousands of these scripts. So when there are adverse events, they should be required to report those to the FDA. Simple. None of that is in this bill. None of it. None of it. Instead, it seeks to put caps on the amount of compounds that can be made by a compound pharmacy without them having to report to the FDA. And then it seeks to codify the definition of essential copy. Again, all of these things that will become law and then argued in court and then a battlefield for Lilly to potentially win a legal battle and thwart compounding. It's creating a new battlefield for them. They're losing in the courts. They're losing with the current language that exists in the Food, Drug, and Cosmetic Act. So we create new language. We create new law. Just vague enough to pull some threads and hopefully win something in court. That's how I see it. You may see it differently. If you do, curious to hear from you. But if you want to fight back against this legislation, you can go to otplinks.com and fight back against that. piece of legislation, because I think that we need as a community to have our voices heard on this, especially those who have gotten healthier by way of compounded medications. So the rumor on the gray market, to get back and close the thought loop here, There's been no specific FDA cutoff announced, but what the rumors going around are that that the compounded versions of GLP ones, especially obesity medicine in the gray market, are all going to turn off like a sieve on January first. Now, I seem to feel like this is probably more of a marketing tactic by these companies to sell a whole bunch of peptides at the end of the year. I think that's probably creating some panic and probably panic buying on people's parts. And so these companies are benefiting greatly. Again, that's why there should be guardrails around this. There's no guardrails around this at all. I mean, at the end of the day, they can say whatever they want to say, so long as they cloak everything in research grade. And these rumors proliferate around and people spend thousands, tens of thousands of dollars. I've heard of people having twenty years worth of Retatrutide in their freezer. Why? For what purpose do you need that? So just a massive amount of money made in this gray market. And that's not to knock people who use it. I say this all the time, but I think it's worth qualifying the statement. It's not knocking people who use it. I get it. But at the same time, we're talking about an industry that is, there's no altruism here. They're in it for money just as much as Eli Lilly is, except they have actually done nothing in the way of advancing medicine. They've just taken intellectual property, copied it, and sold it to you with a label that says, don't put this in your body. So you know where I stand on the gray market. I've heard from many people who've been injured by gray market stuff. It's just what it is. It's a gray market. You're taking your health into your own hands. Please, whatever you're doing out there, as risky as it may be, please involve your doctor and let your doctor know what you're doing so you can be monitored for the things your doctor believes you should be monitored for if you're using this. But this all underscores, again, the need for accessibility to these medications, the need for us to be aware of the fact that a moat is already being built around the most advanced metabolic drug in the pipeline. And we just need to be aware so that when it comes time to fight, we're all ready and informed. And that's what this podcast is serving to do. Before we jump into the next topic, I do want to thank our sponsor, our headline sponsor of this podcast. is a company called Shed. Now, if you are looking for access to care for obesity, then look no further than our partners at Shed who believed in this podcast enough to help us do it full time. You can go to Trished.com and use code OTP25 to save twenty five percent at Trished.com, where you're going to get connected to a doctor who will when medically necessary prescribe medication to treat your obesity. You also get access to coaching. You'll get access to all sorts of medication, whether it's the branded or the compounded versions, depending on your specific situation. All of it is available at Trished.com. They use one of my favorite compound pharmacies in the game, Strive Pharmacy, which I've gotten the chance to dig into on my own. I really love what they do there. They're a It functionally operates a lot more like a 503B. Uh, and I think that they're doing great work over at a strive pharmacy. They partner with shed. So I just love this, this, and when we were looking for somebody to offer a compounded versions, I wanted to make sure that I trusted the pharmacy. People always ask me, Dave, who, who should I go to? I'm like the pharmacy matters more than anything because you want to trust the source of your medication. So try shed.com use code OTP25. Listen, you're going to want to learn about taking any new medication before you take it. Learn about the potential side effects. Learn about the trade offs. There's no free lunch, but all of the information that you're going to need, you can find it. Try shed.com and be familiarizing yourself with all of your options there. So thank you to Shed for being a wonderful partner here at On The Pen. Now let's talk about some data that dropped. We're talking about accessibility and all of the sort of advancements in the world mean very little if people can't access it. That's why I think this data that dropped this past week from our friends over at Rowe is incredible. Absolutely game changing data. So check out this data. Real world telehealth data looking at sixty eight weeks. This is looking at patients who were enrolled in their row body program and on a GLP one specifically some maglutide mean weight loss in this study looked at again patients in over sixty eight weeks. The mean weight loss was sixteen point six percent on average. Thirty three percent of patients lost more than twenty percent and the safety in this study and looking at this data match the clinical trials. So what we're seeing here is that care for obesity can be delivered through a telehealth platform at scale and match clinical trial results. So that scalability decides how many people get access. There are not enough doctors out there to serve the over hundred million people in the United States living with overweight or obesity. so when you hear these blowhard doctors online calling all telehealth platforms except their own a pill mill or as i like to say pin mill the data is actually showing something quite different in that this type of obesity care can be delivered at scale through telehealth platforms it can meet people where they're at and allow people to get care without the shame, without the stigma, without their doctor just pointing to the door and saying, if you want a GLP-I, get out of my office. I ain't going to get it here. How ridiculous. But these people can go to platforms like Rho or Shed or any number of telehealth platforms that are out there and not only get access to medicine, but get access to care. So of course, not all telehealth companies are created equal. Of course, not all compound pharmacies are created equal. You want to do your homework and all of that. But this is data that shows that This kind of care can be delivered at scale via a virtual platform and show similar results to a clinical trial. I think, and this is peer reviewed data, and I think that this is just absolutely great news because when we talk about the problem, we need scalable solutions. The old brick and mortar ain't going to work when you don't have enough doctors to serve enough patients. If we want to get life-changing treatments like ritatratide or terzapatide, semaglutide, whatever, into the hands of the people who need it the most, we need companies to innovate scalable tech platforms that can meet patients where they are, that can leverage current technologies to find people the care that they need. And in this case, it's access to a doctor. It's access to a platform. It's access to prescription medication when appropriately prescribed. And it can be done, and it is being done. So I think this is great news, and will play a huge part in the future. As we talk about Retatrutide, even though it's a year and a half away, maybe a little bit longer, it's already exposing – the issues around accessibility and pricing. Hopefully there will be compounded versions available if they're medically necessitated, if there are shortages. We hope that the battleground for that is not already set and won by Lilly before this drug even comes to market. But there are strategies being done to keep people boxed out But I can tell you that whatever happens with Retatrutide, the future of obesity medicine is in virtual care. And platforms are rising to the occasion. Retatrutide hasn't reached patients yet, but it's already forcing the system to show us, you know, are you ready? Are you ready to deliver bariatric surgery level results at scale to the people who need them? So I am so thankful that you joined me here on this podcast today. Again, we love to talk about we're at a Retatrutide. If you're interested, we've been going live every Monday, Wednesday and Friday at eleven a.m. Central Time here on our YouTube channel, on our tick tock, on our X platform. We're doing that because there's enough news to bring you just about every single day. And we've been doing it for the last couple of weeks. If you've enjoyed it, let me know in the comments of the video on YouTube. Send me an email at David on the pen dot com. Uh, so every single Monday, Wednesday, Friday, and then we do a weekly rundown of the obesity medicine news every Tuesday. That's what this is. The weekly dose podcast. You can catch this on all of the platforms that you listen to your podcasts on, and please make sure to leave us a five star rating and review before you log out of your podcast app. That helps so much. I don't think you guys understand how much that helps, uh, the work that we do here to just train the podcast algorithms that this one is worth listening to. I hope you enjoyed today's podcast. If you did, drop it a thumbs up, five-star review, subscribe on YouTube, do all the things. Thank you for being here, and thank you for being the best part of what we do. We will catch you on the next one. Thank you, my friends. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A mysterious man collapses on the steps of a church with no identification and no explanation — but when patients near him start making impossible recoveries, a nurse discovers his gift comes with a devastating price.IN THIS EPISODE: “The Healing Touch” by Keith ConradFully Produced Version: https://www.auditoryanthology.com/2025/01/28/tales-from-the-blue-line-the-healing-touch/ MORE Stories Like This: https://www.auditoryanthology.com=====Originally aired: December 15, 2025EPISODE PAGE (includes sources): https://weirddarkness.com/TheHealingTouchABOUT WEIRD DARKNESS: Weird Darkness is a true crime and paranormal podcast narrated by professional award-winning voice actor, Darren Marlar. Seven days per week, Weird Darkness focuses on all thing strange and macabre such as haunted locations, unsolved mysteries, true ghost stories, supernatural manifestations, urban legends, unsolved or cold case murders, conspiracy theories, and more. On Thursdays, this scary stories podcast features horror fiction along with the occasional creepypasta. Weird Darkness has been named one of the “Best 20 Storytellers in Podcasting” by Podcast Business Journal. Listeners have described the show as a cross between “Coast to Coast” with Art Bell, “The Twilight Zone” with Rod Serling, “Unsolved Mysteries” with Robert Stack, and “In Search Of” with Leonard Nimoy.#WeirdDarkness #HealingPowers #HospitalHorror #ScaryStories #MedicalMystery #SupernaturalGift #TrueScaryStories #MysteriousStranger #DarkFiction #MiracleHealing

In this episode of Stories Worth Hearing, host John Quick sits down with Dr. Mary Talley Bowden for an open and personal conversation about her journey into medicine and the experiences that shaped her views as a physician. Dr. Bowden reflects on when she first decided to pursue a medical career and how years of working directly with patients influenced her approach to care.The conversation explores what she witnessed during the COVID years that raised serious concerns for her as a doctor, and how those experiences led her to speak more openly about patient choice, informed consent, and trust in the healthcare system. Dr. Bowden also discusses why she founded Americans for Health Freedom, what the organization stands for, and why empowering patients to ask questions and take an active role in their health matters now more than ever.She also shares why she decided to write her book, Dangerous Misinformation: The Virus, the Treatments, and the Lies, and what she hopes readers take away from it. The episode includes reflections on her recent appearance on The Joe Rogan Experience and what it was like stepping onto one of the largest media platforms in the world. This is a thoughtful, human focused conversation about medicine, responsibility, and the real stories behind the headlines.Learn more and explore Dr. Bowden's work:Americans for Health Freedom: https://www.americansforhealthfreedom.org/BreatheMD: https://breathemd.org/Dangerous Misinformation: The Virus, the Treatments, and the Lies: https://amzn.to/48GbiTQ

Join this channel to get access to exclusive members only videos:https://www.youtube.com/channel/UCQTAVxA4dNBCoPdHhX9nnoQ/joinJoin Members Only On My Website. 7 day free trial. Save 25% when you choose an annual Membership plan. Cancel anytime:https://understandingrelationships.com/plansJoin Members Only on Spotify:https://podcasters.spotify.com/pod/show/coachcoreywayne/subscribeHow to know if you're sabotaging your success or if you're simply impatient.In this video coaching newsletter I discuss an email update from a 26 year old viewer who bartends, plays in a band and is living the rockstar lifestyle most guys dream of. However, he got out of a toxic relationship 2 years ago and says he self sabotages his opportunities with women he really likes while he beds countless beautiful women he's not that into. He wonders if maybe he's simply being impatient about meeting a great woman to have a relationship with.If you have not read my book, “How To Be A 3% Man” yet, that would be a good starting place for you. It is available in Kindle, iBook, Paperback, Hardcover or Audio Book format. If you don't have a Kindle device, you can download a free eReader app from Amazon so you can read my book on any laptop, desktop, smartphone or tablet device. Kindle $9.99, iBook $9.99, Paperback $29.99 or Hardcover 49.99. Audio Book is Free $0.00 with an Audible membership trial or buy it for $19.95. Here is the link to Audible to get the audiobook version:https://www.audible.com/pd/B01EIA86VC/?source_code=AUDFPWS0223189MWT-BK-ACX0-057626&ref=acx_bty_BK_ACX0_057626_rh_usHere is the link to Amazon to purchase Kindle, Paperback or Hardcover version:http://amzn.to/1XKRtxdHere is the link to the iBookstore to purchase iBook version:https://geo.itunes.apple.com/us/book/how-to-be-3-man-winning-heart/id948035350?mt=11&uo=6&at=1l3vuUoHere is the link to the iTunes store to purchase the iTunes audio book version:https://geo.itunes.apple.com/us/audiobook/how-to-be-a-3-man-unabridged/id1106013146?at=1l3vuUo&mt=3You can get my second book, “Mastering Yourself, How To Align Your Life With Your True Calling & Reach Your Full Potential” which is also available in Kindle $9,99, iBook $9.99, Paperback $49.99, Hardcover $99.99 and Audio Book format $24.95. Audio Book is Free $0.00 with an Audible membership trial. Here is the link to Audible to get the audiobook version:https://www.audible.com/pd/B07B3LCDKK/?source_code=AUDFPWS0223189MWT-BK-ACX0-109399&ref=acx_bty_BK_ACX0_109399_rh_usHere is the link to Amazon to purchase Kindle, Paperback or Hardcover version:https://amzn.to/2TQV2XoHere is the link to the iBookstore to purchase iBook version:https://geo.itunes.apple.com/us/book/mastering-yourself-how-to-align-your-life-your-true/id1353139487?mt=11&at=1l3vuUoHere is the link to the iTunes store to purchase the iTunes audio book version:https://geo.itunes.apple.com/us/audiobook/mastering-yourself-how-to-align-your-life-your-true/id1353594955?mt=3&at=1l3vuUoYou can get my third book, “Quotes, Ruminations & Contemplations” which is also available in Kindle $9,99, iBook $9.99, Paperback $49.99, Hardcover $99.99 and Audio Book format $24.95. Audio Book is Free $0.00 with an Audible membership trial. Here is the link to Audible to get the audiobook version:https://www.audible.com/pd/B0941XDDCJ/?source_code=AUDFPWS0223189MWT-BK-ACX0-256995&ref=acx_bty_BK_ACX0_256995_rh_usHere is the link to Amazon to purchase Kindle, Paperback or Hardcover version:https://amzn.to/33K8VwFHere is the link to the iBookstore to purchase iBook version:https://books.apple.com/us/book/quotes-ruminations-contemplations/id1563102111?itsct=books_box_link&itscg=30200&ct=books_quotes%2C_ruminations_%26_contemplatio&ls=1

In this episode of the Nifty Thrifty Dentists Podcast, Dr. Glenn Vo sits down with Ali Soufi, Founder & CEO of DocSites, to break down why missed phone calls and poor website lead capture are costing dental practices new patients... and how AI tools can help fix it. Ali shares insights from working with thousands of dental offices and explains how voicemail, after-hours calls, and unanswered website questions create friction in the new patient journey. He also introduces DocSites' AI Support Suite, which includes AI phone answering, AI web chat, and a lead management dashboard designed to help practices capture and follow up on leads without adding staff. If your practice is spending money on dental marketing but still losing opportunities due to missed calls or website bounce-offs, this episode is a must-watch.

Join Elevated GP: www.theelevatedgp.com Register for the live meeting: https://www.theelevatedgp.com/ElevationSummit Download the Injection Molding Guide: https://www.theelevatedgp.com/IMpdf  n Part 1 of this two-part series, Dr. Melissa Seibert sits down with cosmetic dentist and AACD residency preceptor Dr. David Eshom for a powerful conversation that reframes how dentists think about photography, diagnosis, communication, and case acceptance. Drawing from more than 20 years of comprehensive cosmetic dentistry, Dr. Eshom reveals why extraoral photography—not intraoral cameras, not radiographs—is the single most effective tool for building trust and helping patients clearly see the value of comprehensive care. Together, they break down a step-by-step new patient workflow that seamlessly blends diagnostics with psychology, showing how simple point-and-shoot photography placed at the beginning of the exam can elevate patient engagement, differentiate your practice, and eliminate the pressure-based communication styles that leave patients feeling skeptical or overwhelmed. Dr. Eshom explains how co-diagnosis—rooted in permission-based dialogue and visual storytelling—helps patients recognize their own conditions, understand consequences, and ask for solutions rather than being sold to. This episode dives into: The most overlooked use of photography in dentistry: real-time conversation with the patient How to structure a new patient visit that fosters trust, clarity, and long-term case acceptance Why facially generated treatment planning is so effective—especially for patients who "never knew" what their smile looked like Communication strategies that shift patients from an "insurance model" to a value-driven mindset How simplifying photography (yes, even with an iPhone or point-and-shoot) makes comprehensive exams dramatically more effective What to say—and not say—when presenting conditions to avoid making patients feel judged or pressured How this method empowered Dr. Eshom to build a fully fee-for-service practice and drop every insurance plan This conversation is practical, strategic, and deeply grounded in human psychology. If you want a proven communication system that elevates your new patient experience, improves case acceptance, and builds lifelong patient trust—all without feeling salesy—this episode will reshape how you practice.

Pastor Natalie Morris emphasizes the importance of aligning our actions and emotions with the principles of love described in these verses.

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com Patients are now bearing an unsustainable share of healthcare costs, and providers who ignore the financial side of care are putting both outcomes and revenue at risk. In this episode, Seth Cohen, President at Cedar, discusses how the affordability crisis is being felt at the front lines, with patient out-of-pocket costs rising faster than overall medical spending, and the majority of Americans now in high-deductible plans that they often cannot afford. He explains why a small share of uninsured patients generates 35% of the dollars owed and how that financial stress undermines any claim of “healing” if it ends in ruined credit and anxiety. Seth introduces Cedar Cover as a proactive digital coverage safety net that goes beyond billing to connect patients to Medicaid, ACA plans, financial assistance, copay programs, and other benefits, already delivering a 97% success rate in Medicaid applications, pharmacy subsidies, and higher reimbursement on denied claims. Looking ahead, he predicts the crisis will worsen and argues that caring for patients means helping them access every resource.  Tune in and discover how reframing billing as part of care can create mutually beneficial situations for patients and providers. Resources: Connect with and follow Seth Cohen on LinkedIn. Follow Cedar on LinkedIn and discover their website! Learn more about Cedar Cover here.Email Seth directly here.

TODAY ON THE ROBERT SCOTT BELL SHOW: A Sunday Conversation with Dr. Sean Devlin - Artificial Medicine, Restoring Mineral Balance, and the Sacred Doctor-Patient Relationship https://robertscottbell.com/a-sunday-conversation-with-dr-sean-devlin-artificial-medicine-restoring-mineral-balance-and-the-sacred-doctor-patient-relationship/https://boxcast.tv/view/a-sunday-conversation-with-dr-sean-devlin---artificial-medicine-mineral-balance-and-the-sacred-doctor-patient-relationship---the-rsb-show-12-14-25-f86yjihehqzksl46oasn Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

In this episode, Ashley Schutz, Director of IT Quality Assurance at University Health in San Antonio, Texas, shares how her team enhances patient flow and transparency while supporting major technology initiatives, including LeanTaaS' iQueue for Inpatient Flow and the system's broader clinical and IT modernization efforts. This episode is sponsored by LeanTaaS.

This week we sit down with Dr. Shari Brasner, a (semi famous!) OB/Gyn, widely respected for her approach to patient care.Dr. Brasner reflects on how her time at Cornell shaped her path in medicine and shares why the relationship between doctor and patient matters so deeply. Through honest, funny, and sometimes emotional stories, she highlights the impact of trust, communication, and compassion in moments that truly count.This conversation goes beyond credentials. It's about the importance of a great doctor, the human side of medicine, and why thoughtful, attentive care can make all the difference.You will rethink everything.Not sponsored by or affiliated with Cornell University

Behind every safe clinical outcome is a system of supply chain decisions that make it possible. On this episode of Power Supply, we're joined by Jimmy Chung, Chief Medical Officer at Advantus Health Partners, to explore supply chain's role in patient safety—and why preventable medical errors remain a challenge that high-reliability practices can help reduce. From standardization and surgical timeouts to reducing unnecessary variation, Dr. Chung explains how safer care is built through consistent, well-designed systems. He also encourages supply chain professionals to recognize their role as partners in patient safety and confidently contribute their expertise to care delivery decisions. If you're ready to claim your voice in patient safety, this conversation will show you why supply chain is essential to high-reliability healthcare! Once you complete the interview, jump on over to the link below to take a short quiz and download your CEC certificate for 0.5 CECs! – https://www.flexiquiz.com/SC/N/ps16-07 #PowerSupply #Podcast #AHRMM #HealthcareSupplyChain #SupplyChain #PatientSafety #HighReliability #SupplyChainLeadership #Standardization

About Beth McCombs:Elizabeth “Beth” McCombs is the executive vice president and chief technology officer of BD, where she leads the company's global research and development organization. She oversees the full spectrum of innovation—from early-stage concept development to product launch—and ensures the continued advancement of BD's existing portfolio. As a member of the BD Executive Leadership Team, she plays a central role in shaping the company's long-term technology and growth strategy. Beth joined BD in 2019 as Senior Vice President of R&D for the BD Medical segment, co-leading portfolio strategy and major growth initiatives. Before joining BD, she spent over two decades at Johnson & Johnson, including serving as Vice President of R&D for Ethicon, the company's surgical devices franchise. She holds both a B.S. and an M.S. in mechanical engineering from the Massachusetts Institute of Technology and an MBA from the Wharton School of the University of Pennsylvania.Things You'll Learn:BD approaches innovation by deeply studying clinical workflows and ensuring new technologies solve meaningful, scalable problems. Real-world evidence and clinical validation are built into the process from the start.Connected medication management solutions can eliminate waste, prevent errors, and free up clinical resources. Tracking drugs from the central pharmacy to the bedside improves safety and system-level efficiency.Vascular access improvements achieved through product design and standardized training dramatically reduced cost, blood exposure, and catheter failure rates. This proves that outcomes hinge on combining the right device with the right practices.AI and machine-learning capabilities, such as predicting hypotension during cardiac surgery, aim to reduce complications, costs, and length of stay. These tools evolve by partnering with health systems to measure real-world impact.BD Incada represents a shift to cloud-based, interoperable, AI-enabled infrastructure that unifies data across entire health systems. This foundation accelerates the future of personalized care and integrated device ecosystems.Resources:Connect with and follow Beth McCombs on LinkedIn.Follow BD on LinkedIn  and visit their website.

Sermon NotesCLICK HERE

A new technique for delivering radiation to glioblastoma brain tumors may allow doctors to use much higher doses while preserving healthy brain tissue. UT Health San Antonio's Andrew Brenner, MD, PhD, says this may give patients more time.

This week we invited Loose Cannon from The Cobras & Fire Podcast to go track by track through the 13th and final studio album “Patient Number 9” from Ozzy Osbourne. Each month in 2025 we will cover a studio album release by the “Madman” himself Ozzy Osbourne WE NEED YOUR HELP!! It's quick, easy, and free - Please consider doing one or all of the following to help grow our audience: Leave Us A Five Star Review in one of the following places: Apple Podcast Podchaser Spotify Connect with us  Email us growinuprock@gmail.com Contact Form  Like and Follow Us on FaceBook Follow Us on Twitter Leave Us A Review On Podchaser Join The Growin' Up Rock Loud Minority Facebook Group Do You Spotify? Then Follow us and Give Our Playlist a listen. We update it regularly with kick ass rock n roll Spotify Playlist Buy and Support Music From The Artist We Discuss On This Episode Growin' Up Rock Amazon Store Pantheon Podcast Network Official Ozzy Website Music in this Episode Provided by the Following: Ozzy Osbourne, Stolen Prayer If you dig what you are hearing, go pick up the album or some merch., and support these artists. A Special THANK YOU to Restrayned for the Killer Show Intro and transition music!! Restrayned Website Learn more about your ad choices. Visit megaphone.fm/adchoices

What a treat this conversation was for me! I had the pleasure of listening to the fabulous Prof Angie Doshani at the POGP conference in Edinburgh in September - she absolutely rocked the stage and gave an intensely thought provoking presentation on the importance of personalising pelvic health, taking into account cultural, ethnic, religious and language considerations.In this conversation, we talked about:Culturally Sensitive Pelvic Health SupportClinical Communication Strategies for Pelvic PainPatient Self-Assessment for Diverse CareSupporting Women in Culturally Appropriate Pelvic Health SpacesEnhancing Medical Communication with Technologyand much more!As well as being a consultant obstetrican/gynaecologist, Angie is a researcher, professor and a driver of change, as well as the developer of the Janam app, which is leading the way in developing a digital knowledge base to support women's perinatal pelvic health, in a culturally and linguistically appropriate way (currently available in English & 6 other languages).I don't say this lightly but this may have been one of my favourite conversations on the podcast - thought provoking, challenging and inspirational. Let me know what you think!(and just a reminder...if you're listening to this podcast in December...you can use the code PF75 on any (all!) of my online courses, from female pelvic pain, to oncology, from menstrual to menopausal health, bowel health to back pain...but only until Dec31st! All of the course info is on my website CelebrateMuliebrity.com or follow along for my continuing adventures in women's health on instagram (@michellelyons_muliebrity) or...my online group for women's health clinicians on Facebook, Global Pelvic PhysioThanks for listening, let me know what YOU think and until next time...Onwards & Upwards! Mx #celebratemuliebrity

This episode of VHHA's Patients Come First podcast features Stacy Gradowski, Director of Business Development at the Michigan Health Council, who joins us for a conversation about health care workforce development, the ACEMAPP platform to support providers with clinical rotation planning and scheduling, partnering with VHHA Solutions, and more. Send questions, comments, feedback, or guest suggestions to pcfpodcast@vhha.com or contact on X (Twitter) or Instagram using the #PatientsComeFirst hashtag.

Dans ce deuxième épisode de notre série sur les patients experts, je vous emmène dans les coulisses du soin : hôpital, recherche, formation des médecins… Ces sphères que l'on pense réservées aux professionnels s'ouvrent aujourd'hui aux patients. Marion Lanly (AP-HP) et Emmanuelle Hoche (Unicancer) nous montrent comment ces patients, devenus partenaires, transforment le système de santé de l'intérieur. Ensemble, on découvre comment leurs expériences intimes deviennent des leviers d'action collectifs. Grâce à des dispositifs structurés, ce partenariat redéfinit les rôles, les relations, et même l'architecture des lieux de soin. Un mouvement profond, concret, qui interroge aussi les limites de cette nouvelle place donnée aux patients.Dans cet épisode, on aborde :Comment les patients deviennent acteurs de la transformation hospitalièreLe rôle clé des aidants dans le soin et leurs difficultés d'engagementLes méthodes pour intégrer durablement la voix des patients (formation, co-construction…)L'impact du partenariat sur le sens du travail des soignantsDes exemples concrets d'ajustements grâce à l'expérience patient (architecture, soins, formation)Les défis liés à la reconnaissance et au statut des patients partenairesCheminements, c'est le podcast santé des femmes qui parlent de leur santé mentale, physique, et émotionnelle, sans honte, sans filtre et sans tabou. Chaque épisode, diffusé un lundi sur deux, vous plonge dans des récits authentiques et bouleversants.En ouvrant le dictionnaire, on apprend que "cheminement" désigne une progression graduelle, un mouvement, une avancée. Dans ce podcast, le cheminement est celui des femmes : leurs luttes, leurs victoires et leurs transformations face aux défis de la vie et de la santé.Dans Cheminements, le micro est tendu à des femmes du quotidien : vos voisines, collègues, soeurs ou amies. Elles témoignent de leur santé mentale, physique ou sociale, partagent leurs parcours uniques et osent enfin lever le voile sur des sujets trop souvent passés sous silence.Ce podcast santé donne la parole à celles qui méritent d'être entendues. Chaque histoire, portée avec sincérité, met en lumière des réalités humaines, parfois douloureuses, mais toujours humaines.

In this episode "How can we optimise decision-making for complex/high-risk kidney stone patients?"  Prof. Bhaskar Somani (GB) is joined by Dr. Matthew Breeggemann (US) and Dr. Timothy Bryant (GB) to explore the practical value and challenges of multidisciplinary collaboration in stone disease management. The speakers reflect on how shared decision-making within a structured stone MDT can support better outcomes for complex or high-risk recurrent kidney stone patients. Using a real-life case example, they walk through the patient journey, examining how early specialist input and coordinated care can impact diagnosis, treatment planning and follow-up.They discuss the current gaps in guideline implementation, particularly where patient complexity demands input beyond standard urological care. The role of nephrology, radiology and dietetics in MDT decision-making is highlighted, emphasising the need for clear communication and flexible protocols. The speakers also address challenges, such as delays in imaging or conflicting clinical opinions and how MDT formats can help resolve these through consensus-building.The importance of tailoring care to individual risk profiles is underscored, along with suggestions for integrating MDT principles into both large and smaller healthcare systems. The episode concludes with practical recommendations for centres looking to establish or improve a stone MDT. This conversation provides valuable insight for clinicians involved in managing stone disease and those working toward more coordinated care models.You can also listen to the previously released episode:Identifying high-risk stone formers: How can we improve early diagnosis and referral? A discussion between Prof. Somani, Prof. Ferraro and Prof. EmilianiAcknowledgmentMedical writing support was provided by Accenture Song Life Sciences with unrestricted funding from Novo Nordisk, with no involvement in the programme or speaker selection.

A lot of Cash-Pay practices are doing something very smart right now. They're using entry-point services to get new customers in the door… things like specialty services and modalities (like shockwave therapy, red light sauna, etc), performance-based training, etc. And it works… Ads convert. Promotions fill schedules. New Patients and Revenue comes in. But here's the problem I keep seeing in most practices doing this … They struggle to get these new customers to say 'yes' to everything else that could benefit them. For example: pretty much everyone who would benefit from shockwave to speed healing, could benefit even more by getting physical therapy along with the shockwave. Patients come in for one thing. They buy one thing. They leave … even though they clearly need more. Today's episode is about fixing that. Specifically, how to use a brief, intentional assessment and conversation process to help patients see what they actually need, and eagerly say yes to it. Before you click over to the episode, a quick announcement: I'm hiring at my clinic in Austin and could really use your help. If you know any skilled manual physical therapists in Austin (or who might want to move to Austin) who would love to be paid really well to treat every patient 1-on-1 for a full hour, PLEASE forward this to them or send me an email at Jarod@CarterPT.com.  Click here to see the job post and apply. What You'll Learn in This Episode Why entry-point services create a lopsided schedule, overloaded with clients Not getting your core service, and how to avoid that How to use a short assessment to open patients' eyes The exact language that links services to real outcomes How to eliminate "I just want this one thing" patients Why setting expectations early increases commitment and retention USEFUL INFORMATION: Check out our course: Cash-Based Practice Mastermind

On this week's program, an Alzheimer's diagnosis met with courage, curiosity and determination to change the “D” word. Then, after competing in multiple marathons and ironmans, a Navy veteran faces his toughest challenger yet — and every second counts.

What to see an alarming stat? 77% of OBGYNs report that their pregnant patients are declined routine dental care. There is plenty of stigma and misunderstanding swirling about in the dental community regarding pregnant patients, so give this episode with Katrina Sanders as she shares 8 important tips for treating pregnant patients! Resources: More Fast Facts: https://www.ataleoftwohygienists.com/fast-facts/ Katrina Sanders Website: https://www.katrinasanders.com  Katrina Sanders Instagram: https://www.instagram.com/thedentalwinegenist/ 

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com What happens when clinicians have groundbreaking ideas, but no roadmap to bring them to life? In this episode, Dr. Arlen Meyers, Professor Emeritus of Otolaryngology, Dentistry, and Engineering at the University of Colorado School of Medicine and the Colorado School of Public Health, and President and CEO of the Society of Physician Entrepreneurs, discusses how SOPE helps clinicians transform ideas into innovations that reach patients. He explains why most healthcare professionals lack formal entrepreneurship training and how that gap leaves them unsure of what to do with their ideas. He explores the rising challenges of burnout and moral injury in medicine, and how fear, ego, and identity keep many clinicians from pursuing new paths. He also shares how SOPE uses “radical candor,” idea euthanasia, and practical entrepreneurial frameworks to help innovators pivot, persevere, or let go. Tune in to hear how physician innovators can finally connect the dots! Resources Connect with and follow Dr. Arlen Meyers on LinkedIn. Follow the Society of Physician Entrepreneurs on LinkedIn and discover their website!

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com Clean, connected data is becoming the foundation for real progress in patient access, affordability, and care delivery. In this episode, Lynne Nowak, Chief Data and Analytics Officer at Surescripts, shares how her team is using data, automation, and emerging technologies to remove friction across the healthcare system. She explains how greater interoperability improves information flow among providers, payers, pharmacies, and patients, especially benefiting underserved populations. Lynne details how her organization evaluates AI by focusing on its real-world impact, utilizing it for high-value tasks such as reviewing complex medical records for prior authorizations and digitizing benefit verification. She also highlights new insights such as “first-fill abandonment” and previews upcoming work in adherence analytics, price transparency, and direct-to-patient capabilities. Tune in and discover how smarter data, automation, and real-time insights are transforming access, adherence, and the patient experience across the care continuum. Resources Connect with and follow Lynne Nowak on LinkedIn. Follow Superscripts on LinkedIn and visit their website!

"I'll go back to the backpack analogy. When your kids come home with a backpack, all of a sudden their homework is not on the desk where it's supposed to be. It's in the kitchen; it kind of spreads all over the place, but it's still in the house. When we give antibody–drug conjugates (ADCs), the chemotherapy does go in, but then it can kind of permeate out of the cell membrane and something right next to it—another cancer cell that might not look exactly like the cancer cell that the chemotherapy was delivered into—is affected and the chemotherapy goes over to that cancer cell and kills it," ONS member Marisha Pasteris, OCN®, office practice nurse in the breast medicine service at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ADCs in metastatic breast cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Gilead and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 378: Considerations for Adolescent and Young Adult Patients With Metastatic Breast Cancer Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 303: Cancer Symptom Management Basics: Ocular Toxicities ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options Communication Case Study: Talking to Patients About Progressive Metastatic Breast Cancer What Is HER2-Low Breast Cancer? ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin-ejfv Fam-trastuzumab deruxtecan-nxki ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Guide to Breast Care for Oncology Nurses Guide to Cancer Immunotherapy (second edition) ONS courses: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care The Association Between Hormone Receptor Status and End-of-Life Care Among Patients With Metastatic Breast Cancer Oncology Nursing Forum article: Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes ONS huddle cards: Altered Body Image Huddle Card Chemotherapy Huddle Card Targeted Therapy Huddle Card Foundations of Antibody–Drug Conjugate Use in Metastatic Breast Cancer: A Case Study ONS Biomarker Database (refine by breast cancer) ONS Breast Cancer Learning Library American Society of Clinical Oncology (ASCO) homepage Drugs@FDA package inserts National Comprehensive Cancer Network homepage Susan G. Komen metastatic breast cancer page To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "What an ADC is doing is taking the antibody and linking it to a cytotoxic chemotherapy with the idea of delivering it directly into the cell. How I explain this to new nurses or patients is a backpack analogy. If we think of it as a HER2 molecule wearing a chemo backpack, it's going to find the HER2 receptor attached to it and then drop the chemotherapy into the cell via the backpack. Similar to how we come home from work, we open the key to our door, we're carrying all of our items, and then we drop our own personal items in our house." TS 2:30 "The reason that so many patients with metastatic breast cancer are able to receive ADC therapy is because they are targeting two very common antibodies that we see in breast cancer. One is HER2 and the other is trophoblast cell surface antigen 2 (TROP2). These are seen across the board. We see these on triple-negative breast cancers, hormone receptor–positive cancers, and HER2-positive breast cancers. And now we have a new way to talk about HER2, which is a HER2-low. ... Recently, we have found that patients who express low levels of HER2 are able to receive ADC therapy, specifically fam-trastuzumab deruxtecan." TS 4:21 "Another [ADC] that has just been approved is datopotamab deruxtecan. This is another ADC that targets the TROP2 receptor on a cancer cell. This one carries a lot of side effects. I mentioned earlier that you need an ophthalmology clearance because there is a lot of ocular toxicity around this one. We see a lot of blepharitis, conjunctivitis, there can be blurred vision. Another thing we monitor on this one is mucositis. In the package insert, there's a recommendation for using ice chips while receiving the treatment. ... Then in the HER2-positive and HER2-low space is the big one, which is fam-trastuzumab deruxtecan. This was approved in 2019 for the HER2-positive patients, then more recently in the HER2-low [patients]. The big [side effect] with this one is interstitial lung disease." TS 10:11 "Interstitial lung disease is an inflammation or a little bit of fibrosis within the lung that causes an impaired exchange between the oxygen and carbon dioxide. This was seen in the clinical trials, specifically around fam-trastuzumab deruxtecan. During the trials, they had a very small percentage, I think it was 1%, that died due to interstitial lung disease. So, this is a very important side effect for us as nurses to be aware of. It typically presents in patients like a dyspnea. A lot of times, it's like, 'Well, I used to be able to walk my kid to the bus stop, but now when I walk there, I feel really short of breath.' Or 'I've had this dry cough for the past couple weeks and I've tried medications, but haven't had that relieved.' So, we really need to be aware of that because early intervention in interstitial lung disease is key." TS 12:57 "ADCs are toxic drugs. They have the benefit of being targeted, but we know that they carry a lot of side effects. ... Their specificity makes them so wonderful and we've seen amazing responses to these drugs. But also, we want patients to be safe. We want to give these drugs safely. So, we have to assess our patients and make sure that this is an appropriate patient to give this therapy to. I think that's an open conversation that clinicians need to have with patients regarding these drugs." TS 18:08

Hour 2 of A&G features... Judge Larry Goodman talks to A&G about cameras in the courtroom Epstein news & Walmart removing dyes Obamacare & costs Patient records doctor while going through procedure See omnystudio.com/listener for privacy information.

In this episode Dr. Howland sits down with patient and friend Jenny Hill to talk about her journey. Jenny lost nearly 200 pounds, she is a cancer survivor, and she has an absolutely incredible story of strength, resilience, and love. Tune in!

What happens when clinicians stop hearing the very people they're trying to help? In this episode, Dr. Rageshri Dhairyawan, a Consultant Physician in Sexual Health and HIV Medicine at Barts Health NHS Trust and Deputy Director of the SHARE Collaborative at Queen Mary University of London, discusses how patients are often disbelieved or dismissed in healthcare. She shares her own experience of being ignored during a painful hospitalization, which revealed how difficult it can be for even a senior doctor to speak up when vulnerable. Dhairyawan argues that medicine has a long-standing culture of skepticism toward patient testimony, which harms trust, exacerbates inequities, and undermines care. She urges systemic and educational reforms, more time, continuity, staff wellbeing, training in true listening, and structural support for patient voices. While acknowledging resource constraints, she emphasizes that listening is both therapeutic and essential to restoring humanity in healthcare. Tune in to hear Dr. Rageshri Dhairyawan unpack why patients often feel unheard, and how listening might be healthcare's most powerful, yet overlooked, tool. Resources Connect with and follow Dr. Rageshri Dhairyawan on LinkedIn and visit her website! Follow Barts Health NHS Trust on LinkedIn and explore their website! Follow Queen Mary University of London on LinkedIn and discover their website! Check out Dr. Dhairyawan's book, Unheard: The Medical Practice of Silencing, here! Learn more about your ad choices. Visit megaphone.fm/adchoices

Brian From reflects on the emotional rollercoaster of sports fandom, Time Magazine’s Person of the Year, and why dark chocolate might help you live longer—even if he refuses to eat it. He explores the deeper spiritual challenge of Christmas: not consumerism or secularism, but our own boredom with the most astonishing story ever told. The episode closes with a sobering look at the Michigan football scandal as a reminder that sin always destroys—and the gospel always restores. Dark Chocolate Compound Linked To Slower Aging Thief Said He Was "Teleported” Into Stolen BMW | The Smoking Gun Fascinating on X: "Adolf (Adi) and his older brother Rudolph (Rudi) Dassler, born in Germany, established the world's first sports shoe company, Gebrüder Dassler Schuhfabrik, achieving global fame when athletes clinched 17 medals at the 1936 Berlin Olympics in their footwear, including four golds https://t.co/jKXW1DH6rh" / X Desiring God on X: "Where do you place your hope in the hardest times? We are not promised an easy life, but we are promised a hope to carry us through every tribulation and trial: That hope is Jesus. Sermon: “Happy in Hope, Patient in Pain, Constant in Prayer” https://t.co/YDcQJy8X4b" / X Bend Toward the Light - Christianity Today RightNow Media on X: "Jesus is too wonderful for words to fully describe.

Featuring perspectives from Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields, moderated by Dr Stephen "Fred" Divers, including the following topics:  Introduction (0:00) Targeted Therapy for Non-Small Cell Lung Cancer (NSCLC) — Dr Gainor, MD (5:32) Case: A woman in her mid 60s with ALK-mutant metastatic adenocarcinoma of the lung (PD-L1 TPS 70%) — Zanetta S Lamar, MD (17:59) Case: A woman in her mid 80s with EGFR exon 19-deleted adenocarcinoma of the lung with recurrence after 4 years of osimertinib — Jennifer Yannucci, MD (27:53) Case: A woman in her late 60s with HER2-mutant metastatic adenocarcinoma of the lung — Brian P Mulherin, MD (39:41) Case: A man in his early 70s with locally recurrent squamous cell carcinoma of the lung and a MET exon 14 skipping mutation — Sean Warsch, MD (46:39) Case: A woman in her early 70s with ROS1-mutant metastatic adenocarcinoma of the lung that responds to entrectinib and then to pembrolizumab/carboplatin/pemetrexed administered upon disease progression — Dr Yannucci (52:44) Nontargeted Therapy for NSCLC; Small Cell Lung Cancer — Dr Langer (58:16) Neoadjuvant, Perioperative and Adjuvant Anti-PD-1/PD-L1 Antibody-Based Approaches for Patients with Localized NSCLC — Dr Shields (1:14:14) Case: A man in his mid 60s with localized adenocarcinoma of the lung who receives neoadjuvant cisplatin/pemetrexed/pembrolizumab and achieves a pathologic complete response — Dr Mulherin (1:23:19) Case: A man in his early 60s with metastatic mixed adenosquamous NSCLC (PD-L1 TPS 50%) — Sunil Babu, MD (1:30:04) Case: A man in his late 50s diagnosed with extensive-stage small cell lung cancer who receives carboplatin/etoposide/durvalumab — Dr Warsch (1:34:07) CE information and select publications

The Big Unlock · Lisa Hunter, Senior Director of Federal Policy & Advocacy, United States of Care In this episode, Lisa Hunter, Senior Director of Federal Policy and Advocacy at United States of Care, discusses how her organization is working to ensure every American has access to affordable, high-quality care, with a particular focus on rural communities. She explains the new Rural Health Transformation Program—a 50-billion-dollar, five-year federal investment that gives states a rare opportunity to redesign rural health delivery, address workforce gaps, and move toward “patient first care” models that emphasize coordination, whole-person care, and sustainable payment structures.​​ Lisa highlights a growing trust gap around AI in healthcare, noting that patients are more comfortable with AI in back-office and ambient use cases compared to roles that feel like they replace clinicians. She stresses the need for rigorous listening, research, and language that resonates with people, so policy and technology decisions reflect real experiences rather than abstract concepts. Take a listen.

During this episode, I plan to discuss the latest in cannabis policy news. I also plan to roll out a fresh new look for the show. Watch video version and read full show notes here: https://thecolememo.com/2025/12/11/e240/

Hour 2 of A&G features... Judge Larry Goodman talks to A&G about cameras in the courtroom Epstein news & Walmart removing dyes Obamacare & costs Patient records doctor while going through procedure See omnystudio.com/listener for privacy information.

This is the 69th episode in my drug pronunciation series. In this episode, I divide Kisunla and donanemab-azbt into syllables, tell you which syllables to emphasize, and share my sources. The written pronunciations are below and in the show notes on https://www.thepharmacistsvoice.com. Special thanks to Megan Hull, PharmD for inspiring me to pick Kisunla for this series. She mentioned it during the CE session she led at the Midyear Meeting of the Ohio Pharmacists Association in Nov 2025.   Note: we don't cover pharmacology in this series. Just pronunciations.   ⭐️Sign up for The Pharmacist's Voice ® monthly email newsletter! https://bit.ly/3AHJIaF ⭐️   Kisunla = kih-SUHN-lah kih, like kiss SUHN, like sunshine lah, like lullaby Emphasize SUHN Written pronunciation source: Medication Guide for Kisunla on https://kisunla.lilly.com/ (accessed 12-10-25). Spoken pronunciation example: Patient testimonial video https://kisunla.lilly.com/patient-stories (accessed 12-10-25).   Donanemab-azbt = doe-NAN-e-mab A-Z-B-T doe, as in a female deer NAN, like the woman's name, Nancy e, which is a short "E" sound or a schwa "E" sound mab, which is the stem (or suffix) for a monoclonal antibody Emphasize NAN Written pronunciation sources: USP Dictionary Online and medlineplus.gov. (accessed 12-10-25)  Spoken pronunciation example by Ronald Petersen MD, PhD YouTube video on Mayo Clinic's YouTube Channel (accessed 12-10-25)   If you know someone who would like to learn how to say Kisunla and donanemab-azbt, please share this episode with them. Subscribe for all future episodes. This podcast is on all major podcast players and YouTube. Popular links are below. ⬇️   Apple Podcasts   https://apple.co/42yqXOG  Spotify  https://spoti.fi/3qAk3uY  Amazon/Audible  https://adbl.co/43tM45P YouTube https://bit.ly/43Rnrjt   Host Background: Kim Newlove has been an Ohio pharmacist since 2001 (BS Pharm, Chem Minor). Her experience includes hospital, retail, compounding, and behavioral health. She is also an author, voice actor (medical narrator and audiobook narrator), podcast host, and consultant (audio production and podcasting).    Other episodes in this series The Pharmacist's Voice Podcast Episode 358, Pronunciation Series Episode 68 (Journavx) The Pharmacist's Voice Podcast Episode 356, Pronunciation Series Episode 67 (Zanaflex) The Pharmacist's Voice Podcast Episode 352, Pronunciation Series Episode 66 (Yescarta) The Pharmacist's Voice Podcast Episode 350, Pronunciation Series Episode 65 (Xarelto) The Pharmacist's Voice Podcast Episode 349, Pronunciation Series Episode 64 (acetaminophen) The Pharmacist's Voice Podcast Episode 348, Pronunciation Series Episode 63 (Welchol/colesevelam) The Pharmacist's Voice Podcast Episode 346, Pronunciation Series Episode 62 (valacyclovir) The Pharmacist's Voice Podcast Episode 343, Pronunciation Series Episode 61 (ubrogepant) The Pharmacist's Voice Podcast Episode 341, Pronunciation Series Episode 60 (topiramate) The Pharmacist's Voice Podcast Episode 339, Pronunciation Series Episode 59 (Suboxone) The Pharmacist's Voice Podcast Episode 337, Pronunciation Series Episode 58 (rosuvastatin)  The Pharmacist's Voice Podcast Episode 335, Pronunciation Series Episode 57 (QVAR) The Pharmacist's Voice Podcast Episode 333, Pronunciation Series Episode 56 (pantoprazole)  The Pharmacist's Voice Podcast Episode 330, Pronunciation Series Episode 55 (oxcarbazepine) The Pharmacist's Voice Podcast Episode 328, Pronunciation Series Episode 54 (nalmefene) The Pharmacist's Voice Podcast Episode 326, Pronunciation Series Episode 53 (Myrbetriq) The Pharmacist's Voice Podcast Episode 324, Pronunciation Series Episode 52 (liraglutide)  The Pharmacist's Voice Podcast Episode 322, Pronunciation Series Episode 51 (ketamine) The Pharmacist's Voice Podcast Episode 320, Pronunciation Series Episode 50 (Jantoven) The Pharmacist's Voice Podcast Episode 318, Pronunciation Series Episode 49 (ipratropium) The Pharmacist's Voice Podcast Episode 316, Pronunciation Series Episode 48 (hyoscyamine) The Pharmacist's Voice Podcast Episode 313, Pronunciation Series Episode 47 (guaifenesin) The Pharmacist's Voice Podcast Episode 311, Pronunciation Series Episode 46 (fluticasone) The Pharmacist's Voice Podcast Episode 309, Pronunciation Series Episode 45 (empagliflozin) The Pharmacist's Voice Podcast Episode 307, Pronunciation Series Episode 44 (dapagliflozin) The Pharmacist's Voice Podcast Episode 304, Pronunciation Series Episode 43 (cetirizine)  The Pharmacist's Voice Podcast Episode 302, Pronunciation Series Episode 42 (buspirone)  The Pharmacist's Voice Podcast Episode 301, Pronunciation Series Episode 41 (azithromycin) The Pharmacist's Voice Podcast Episode 298, Pronunciation Series Episode 40 (umeclidinium) The Pharmacist's Voice Podcast Episode 296, Pronunciation Series Episode 39 (Januvia)  The Pharmacist's Voice Podcast Episode 294, Pronunciation Series Episode 38 (Yasmin) The Pharmacist's Voice Podcast Episode 292, Pronunciation Series Episode 37 (Xanax, alprazolam) The Pharmacist's Voice Podcast Episode 290, Pronunciation Series Episode 36 (quetiapine)  The Pharmacist's Voice Podcast Episode 287, pronunciation series ep 35 (bupropion) The Pharmacist's Voice Podcast Episode 285, pronunciation series ep 34 (fentanyl) The Pharmacist's Voice Podcast Ep 281, Pronunciation Series Ep 33 levothyroxine (Synthroid) The Pharmacist's Voice ® Podcast Ep 278, Pronunciation Series Ep 32 ondansetron (Zofran) The Pharmacist's Voice ® Podcast Episode 276, pronunciation series episode 31 (tocilizumab-aazg) The Pharmacist's Voice ® Podcast Episode 274, pronunciation series episode 30 (citalopram and escitalopram) The Pharmacist's Voice ® Podcast Episode 272, pronunciation series episode 29 (losartan) The Pharmacist's Voice Podcast Episode 269, pronunciation series episode 28 (tirzepatide) The Pharmacist's Voice Podcast Episode 267, pronunciation series episode 27 (atorvastatin)  The Pharmacist's Voice Podcast Episode 265, pronunciation series episode 26 (omeprazole) The Pharmacist's Voice Podcast Episode 263, pronunciation series episode 25 (PDE-5 inhibitors) The Pharmacist's Voice Podcast Episode 259, pronunciation series episode 24 (ketorolac) The Pharmacist's Voice ® Podcast episode 254, pronunciation series episode 23 (Paxlovid) The Pharmacist's Voice ® Podcast episode 250, pronunciation series episode 22 (metformin/Glucophage) The Pharmacist's Voice Podcast ® episode 245, pronunciation series episode 21 (naltrexone/Vivitrol) The Pharmacist's Voice ® Podcast episode 240, pronunciation series episode 20 (levalbuterol) The Pharmacist's Voice ® Podcast episode 236, pronunciation series episode 19 (phentermine)  The Pharmacist's Voice ® Podcast episode 228, pronunciation series episode 18 (ezetimibe) The Pharmacist's Voice ® Podcast episode 219, pronunciation series episode 17 (semaglutide) The Pharmacist's Voice ® Podcast episode 215, pronunciation series episode 16 (mifepristone and misoprostol) The Pharmacist's Voice ® Podcast episode 211, pronunciation series episode 15 (Humira®) The Pharmacist's Voice ® Podcast episode 202, pronunciation series episode 14 (SMZ-TMP) The Pharmacist's Voice ® Podcast episode 198, pronunciation series episode 13 (carisoprodol) The Pharmacist's Voice ® Podcast episode 194, pronunciation series episode 12 (tianeptine) The Pharmacist's Voice ® Podcast episode 188, pronunciation series episode 11 (insulin icodec)  The Pharmacist's Voice ® Podcast episode 184, pronunciation series episode 10 (phenytoin and isotretinoin) The Pharmacist's Voice ® Podcast episode 180, pronunciation series episode 9 Apretude® (cabotegravir) The Pharmacist's Voice ® Podcast episode 177, pronunciation series episode 8 (metoprolol)  The Pharmacist's Voice ® Podcast episode 164, pronunciation series episode 7 (levetiracetam) The Pharmacist's Voice ® Podcast episode 159, pronunciation series episode 6 (talimogene laherparepvec or T-VEC)  The Pharmacist's Voice ® Podcast episode 155, pronunciation series episode 5 Trulicity® (dulaglutide)  The Pharmacist's Voice ® Podcast episode 148, pronunciation series episode 4 Besponsa® (inotuzumab ozogamicin) The Pharmacist's Voice ® Podcast episode 142, pronunciation series episode 3 Zolmitriptan and Zokinvy The Pharmacist's Voice ® Podcast episode 138, pronunciation series episode 2 Molnupiravir and Taltz The Pharmacist's Voice ® Podcast episode 134, pronunciation series episode 1 Eszopiclone and Qulipta   Kim's websites and social media links: ✅ Guest Application Form (The Pharmacist's Voice Podcast) https://bit.ly/41iGogX ✅ Monthly email newsletter sign-up link https://bit.ly/3AHJIaF  ✅ LinkedIn Newsletter link https://bit.ly/40VmV5B ✅ Business website https://www.thepharmacistsvoice.com ✅ Get my FREE eBook and audiobook about podcasting ✅ The Pharmacist's Voice ® Podcast https://www.thepharmacistsvoice.com/podcast ✅ Drug pronunciation course https://www.kimnewlove.com  ✅ Podcasting course https://www.kimnewlove.com/podcasting  ✅ LinkedIn https://www.linkedin.com/in/kimnewlove ✅ Facebook https://www.facebook.com/kim.newlove.96 ✅ Twitter https://twitter.com/KimNewloveVO ✅ Instagram https://www.instagram.com/kimnewlovevo/ ✅ YouTube https://www.youtube.com/channel/UCA3UyhNBi9CCqIMP8t1wRZQ ✅ ACX (Audiobook Narrator Profile) https://www.acx.com/narrator?p=A10FSORRTANJ4Z ✅ Start a podcast with my coach, Dave Jackson from The School of Podcasting! *New 12-4-25* Click my affiliate link: https://community.schoolofpodcasting.com/invitation?code=G43D3G    Thank you for listening to episode 360 of The Pharmacist's Voice ® Podcast.  If you know someone who would like this episode, please share it with them!

Raymond Nistor-Gallo, Kurt Zatloukal, Karin Schwenoha. Regulatory Fragmentation in Europe and Its Risks for Patient Access and Safety: Subcontracting Work Flow Steps of In-House Diagnostic Procedures. Clinical Chemistry, Volume 71, Issue 12, December 2025, Pages 1202–1211. https://doi.org/10.1093/clinchem/hvaf123

One of my brave patients shares her story with lichen sclerosis from being dismissed and told it was "all in her head" to finding proper treatment and relief.I'll never forget the day Jess walked into my office. By the time she found me, she'd already been dismissed by multiple doctors including specialists at what was supposed to be one of Chicago's premier women's health centers. They told her the severe pain and skin changes she was experiencing were "all in her head." Two different physicians suggested she needed a therapist, not medical treatment. Her depression history was weaponized against her, used as proof that she was just being hysterical.But Jess wasn't hysterical. She had advanced lichen sclerosis, and her vulvar skin was literally fusing together. Had she not found proper treatment, she would never have been able to have penetrative sex again. Even worse, without treatment, her risk of vulvar cancer would have climbed from 1% to 3-5%. Yet nobody had explained any of this to her. She'd been handed a tube of clobetasol and essentially told to figure it out herself which she did, on YouTube, learning the proper application technique that her doctors never bothered to teach her.In this episode, Jess bravely shares her journey living with lichen sclerosis—from the devastating experience of being gaslit by female physicians to finding relief through injectable steroids and surgical lysis of adhesions. We talk about how her symptoms worsened when she entered menopause in her mid-40s (common with autoimmune conditions), the complete loss of libido that left her sobbing when a doctor said "it's never coming back," and the body changes that made her feel like a "potato."But this conversation is about more than just lichen sclerosis. It's about the failures of our healthcare system, the importance of advocating for yourself even when you're furious and exhausted, and learning to accept yourself exactly where you're at. Jess's story will resonate with anyone who's ever been dismissed, anyone struggling with vulvar health issues, and anyone navigating the chaos of menopause while trying to hold onto their sense of self-worth.Highlights:Why most gynecologists miss lichen sclerosis (hint: they're not actually looking at your vulva).The proper way to apply clobetasol that doctors don't teach.How vaginismus became a catch-all diagnosis for any woman with painful sex.The We Do Not Care Club movement and redefining your value at midlife.What it means when influencers are the face of menopause marketing.If you've been dismissed or told your vulvar symptoms are "all in your head," this episode validates your experience and shows you're not alone. And if you're a clinician, this is your wake-up call we can no longer dismiss women's symptoms as psychological when real physical disease is staring us in the face. Please share this with someone who needs to hear that their symptoms are real and treatment is available.Get in Touch with Me: WebsiteInstagramYoutubeSubstack

Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcomaOsteosarcoma Webinar Series: Katie Janeway, MD and Suzanne Forrest, MD join us on OsteoBites to discuss results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma.Dr. Janeway received her MD and MMSc from Harvard Medical School. She completed her pediatrics residency and her Pediatric Hematology-Oncology fellowship at Boston Children's Hospital and Dana-Farber Cancer Institute. She is an Associate Professor of Pediatrics, a Senior Physician who cares for young people with sarcoma, and Director of Clinical Genomics. Dr. Janeway's research is focused on precision oncology and bone sarcomas. She leads clinical trials both as an independent investigator and as the Chair of the Children's Oncology Group (COG) Bone Tumor Committee. The Janeway Laboratory leads several studies, which have enrolled and sequenced more than 2,500 patients with childhood cancers. They are using this data to deepen the understanding of clinical and genomic factors explaining prognosis and treatment response, and resistance, with a focus on sarcomas. In collaboration with Count Me In, the group is innovating patient partnerships in sarcoma research.Dr. Forrest completed her medical school training at Yale University, followed by pediatrics training in the Boston Combined Residency Program. She then pursued a pediatric oncology fellowship at Dana-Farber Cancer Institute / Boston Children's Hospital. Currently, she serves as an Assistant Professor of Pediatrics at Harvard Medical School and an Attending Physician in the Department of Hematology/Oncology at Dana-Farber / Boston Children's Cancer and Blood Disorders Center. Her research focuses on developing novel clinical trials that utilize cancer genomics to guide treatment strategies for pediatric solid tumors.After a short presentation on this research, they will take questions from attendees. Share your questions in advance with us at Christina@MIBAgents.org.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RCF865. CME/AAPA credit will be available until December 8, 2026.Contemporary Insights on Diagnosing and Treating Transthyretin Cardiac Amyloidosis: How I Think, How I Treat In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/MNA865. CME/MOC/CC/AAPA credit will be available until November 18, 2026.The Type 2 Inflammation Connection in CRSwNP: Optimizing Patient Identification and Targeted Treatments In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

The difference between good care and unforgettable care often comes down to one thing: personal touch.In this episode, Michael brings on Dr. Kris Bano to unpack the revolutionary strategies behind his standout fee-for-service practice in southwest Michigan. Dr. Bano reveals how his team works in harmony, crafting a seamless, “high-touch” patient experience that starts with the initial phone call and extends well beyond the treatment room.Dr. Bano's journey is deeply personal, rooted in his passion for art and transforming smiles through cosmetic dentistry. Here, he shares the bold decision to eliminate all insurance contracts, putting personalized care above volume, and dives into the systems his practice uses to set itself apart: from detailed communication workflows and an innovative “triangle” approach to patient care, to smart tech adoption for marketing and call tracking. Hear Dr. Bano's candid reflections on building a team based on empathy and continuous learning through coaching and how he balances being a leader, entrepreneur, and family man. He proves it's possible to design a practice that is financially robust, patient-focused, and personally fulfilling.What You'll Learn in This Episode:How a team of dentists with varied specialties collaborates for comprehensive careWhy dropping insurance contracts can elevate patient relationships and practice visionThe secret behind Dr. Bano's “triangle” approach to personalized patient careBest practices for high-touch communication and efficient patient intakeThe key personality traits to look for when hiring exceptional team membersHow data-driven tools like CallRail enhance marketing and monitor patient callsInsights into choosing the right coaching or marketing agency for your practiceStrategies for maintaining work-life balance as a dental practice ownerThe role of consistent vision and trust in building patient loyaltyActionable steps to becoming a high-performing, fee-for-service dental practiceTune in now to discover how you can create a patient-focused dental practice (and a more balanced life) straight from Dr. Bano's playbook!‍Sponsors:‍CallRail: Call tracking + AI that turns calls into campaigns that convert, quality patients, and cost savings. Click our link to start a free trial today! https://www.callrail.com/dentalmarketerClick here for a special offer!Guest: Dr. Kris BanoPractice Name: Centreville Family DentistryCheck out Kris's Media:‍Website: https://www.smilecentreville.com/Instagram: https://www.instagram.com/kbdentistry/YouTube: https://www.youtube.com/@ClinicalClimbTikTok: https://www.tiktok.com/@drkrisbano‍Host: Michael AriasJoin my newsletter: https://thedentalmarketer.lpages.co/newsletter/‍Join this podcast's Facebook Group: The Dental Marketer Society‍Love the Podcast? Let Us Know How We're Doing on Apple Podcasts!‍‍

In this episode of the Less Insurance Dependence Podcast, co-host Don Adeesha sits down with Naren Arulrajah, CEO of Ekwa Marketing, to unpack one of the biggest opportunities in dentistry today: attracting more fee-for-service patients. With nearly half of Americans lacking dental insurance, dentists have a massive untapped market—but many are stuck thinking like PPO-based providers instead of value-based clinicians. Naren explains the essential mindset shift dentists must make, how to communicate value with confidence, and the marketing foundations that help practices break free from PPO dependence. From SEO and Google reviews to membership plans and long-term patient relationships, this episode provides a clear roadmap for dentists ready to elevate their practice, charge what they're worth, and attract patients who genuinely value quality care. Book your free marketing strategy meeting with Ekwa at your convenience. Plus, at the end of the session, get a free analysis report to find out where your practice stands online. It's our gift to you! https://www.lessinsurancedependence.com/marketing-strategy-meeting/   If you're looking to boost your case acceptance rates and enhance patient communication, you can schedule a Coaching Strategy Meeting with Gary Takacs. With his experience in helping practices thrive, Gary will work with you on personalized coaching, ensuring you and your team are prepared to present treatment plans confidently, offer financing options, and communicate the value of essential dental services. https://www.lessinsurancedependence.com/csm/ 

More than 100 million people in the U.S. have some allergy each year. That's about every 1 in 3 adults. For many, the fix is a bandaid: over-the-counter allergy medications. But there's another treatment that works to lessen these reactions rather than just manage people's symptoms, allergy shots. The treatment has been around for over a century and is still popular today. Patients have to take the shots for a few years, and it's the closest thing science has to a cure. Host Regina G. Barber speaks with Dr. Gina Dapul-Hidalgo about how this immunotherapy works and how certain guidelines to keep your child from developing common food allergies have changed.Interested in more science behind allergies? Check out our other episodes:Having a food allergy? And how your broken skin barrier might be the causeSpring Allergies and what to do about themHave another topic on human biology or consumer health you want us to investigate? Email us your question at shortwave@npr.org.Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

In this episode of American Potential, host David From talks with Ohio Representative Jennifer Gross, a retired Air Force combat lieutenant colonel and longtime nurse practitioner, about her push to modernize Ohio's outdated healthcare rules. Rep. Gross explains how Ohio's Standard Care Arrangement requirement blocks highly trained nurse practitioners from providing care they're fully certified to deliver—especially harming patients in rural and underserved communities. She walks through why removing this mandate would: Expand access to doctors and nurse practitioners across Ohio Reduce wait times and improve patient choice Lower costs for patients and Medicaid Follow the lead of 27 states and 3 territories that have already done it She also shares how Ohio suspended the rule during COVID with no increase in patient harm, proving the system works without the red tape. Rep. Gross urges Ohioans to contact their legislators and support HB 508, the Better Access to Healthcare Act. A powerful conversation about healthcare freedom, patient choice, and letting professionals practice to the full extent of their training.